P2.09 A non-viral, GNE-lipoplex treatment to correct sialylation defects in hereditary inclusion body myopathy (HIBM)
Tal Yardeni(Sheba Medical Center), Marjan Huizing(National Human Genome Research Institute), Irini Manoli(National Human Genome Research Institute), John Nemunaitis(Gradalis (United States)), William A. Gahl(National Institute of Child Health), Chris Jay(Gradalis (United States)), Yair Anikster(Edmond and Lily Safra Children's Hospital), Carla Ciccone(National Institutes of Health), Shelley Hoogstraten-Miller(National Human Genome Research Institute), Phillip B. Maples(Gradalis (United States)), Daniel Darvish(Encino Hospital Medical Center)
Cited by 0
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|719
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|1999|497
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer
|Science Translational Medicine|2015|438
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
|Journal for ImmunoTherapy of Cancer|2017|320